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ABSTRACT 
 
Histamine is a critical mediator of IgE/mast cell-mediated anaphylaxis, a neurotransmitter and a 
regulator of gastric acid secretion. Histamine is a monoamine synthesized from the amino acid 
histidine through a reaction catalyzed by the enzyme histidine decarboxylase (HDC), which 
removes carboxyl group from histidine. Despite the importance of histamine, transcriptional 
regulation of HDC gene expression in mammals is still poorly understood. In this Review, we 
focus on discussing advances in the understanding of molecular regulation of mammalian 
histamine synthesis. 
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INTRODUCTION 
 
Bill Paul’s impact on immunology is broad and enormous.  Like many of his former trainees, I 
had the good fortune to learn from him.  Bill’s mentorship has nurtured my lifelong interest in 
studying type 2 immune responses that cause allergic diseases and protect against parasitic 
infections.  In the early years of my laboratory, we had investigated how naïve CD4+ T cells 
commit into T helper type 1 (Th1) cells by silencing the potential to transcribe the Il4 gene (1-3).  
More recently, we extended our efforts to understand how a bi-potential basophil and mast cell 
progenitor acquires the capacity to transcribe a set of basophil-specific or mast cell-specific 
genes while simultaneously repressing transcription of a gene set that is specific for the other cell 
type (4). With a newly gained understanding of a network of transcription factors and their 
targeted enhancers (5), our laboratory has chosen to investigate the Hdc gene (encode histidine 
decarboxylase, a rate-limiting enzyme for histamine synthesis) in greater detail. 
 
Anaphylaxis is a serious allergic reaction that is rapid in onset and includes signs and symptoms 
that involve the skin, gastrointestinal track, respiratory system and cardiovascular system (6). 
The most severe form of anaphylaxis is anaphylactic shock, which is characterized by 
hypotension and can cause death (6). Anaphylaxis can be caused by allergy to foods, insect 
venoms, medications and other agents (6). The incidence of food-induced anaphylaxis has risen 
at an alarming rate, especially in children, in developed countries during the past several decades 
and continues to rise (7-9). The economic burden of food allergy is staggering with an estimated 
cost of 25 billion dollars annually in the US alone (10). 
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Histamine plays an essential role in IgE-medicated anaphylaxis, the most common type of 
anaphylaxis (11-14).  Histamine was first purified from ergot fungi (15) in 1910 and from human 
tissues (16) in 1927. Histamine has pleiotropic effects on skin and the cardiovascular, 
respiratory, digestive, central nervous and immune systems (17). It is a profound vasodilator that 
increases blood vessel permeability, allowing blood leukocytes to enter tissues to promote 
inflammatory responses. Relatively large quantities of histamine can cause a rapid decrease in 
body temperature due to massive leakage of blood plasma into the extravascular space. Rapid 
release of large amounts of histamine leads to anaphylaxis (12, 14). Histamine belongs to a 
family of biogenic amines that includes neurotransmitters, such as serotonin and dopamine, and 
hormones, such as epinephrine. Biogenic amines that contain one or more amine groups are 
formed mainly by decarboxylation of amino acids. Histamine is a monoamine synthesized from 
the amino acid histidine through a reaction catalyzed by the enzyme histidine decarboxylase 
(HDC), which removes carboxyl group from histidine (Figure 1). Although histamine can be 
synthesized by bacteria found in contaminated food (18) and in the gut of asthma patients (17, 
19), in this Review, we focus on discussing advances in the understanding of molecular 
regulation of mammalian histamine synthesis. 
 
HISTAMINE-PRODUCING CELLS IN MAMMALS AND STIMULI THAT TRIGGER 
HISTAMINE RELEASE 
Histamine is synthesized primarily by mast cells, basophils, histaminergic neurons in the basal 
ganglia of the brain and enterochromaffin-like cells (ECL) in the stomach. These cells produce 
large amounts of histamine and are thought to be the major histamine-producing cells (Figure 2).  
They continuously synthesize histamine, which is then linked to the carboxyl group of heparin 
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and stored in intracellular granules until the cells receive the appropriate activating stimulus.  
Upon external stimulation, these cells degranulate, releasing the stored histamine.  Stimuli that 
trigger histamine release by these major histamine-producing cells have been reviewed 
extensively (20-25).  Antigen crosslinking of antigen-specific IgE bound to the high affinity IgE 
receptor, FcεRI, on the mast cell and basophil surface is the most robust stimulus that triggers 
histamine release by these cells (20-23).  Substance P and allergy-inducing drugs that bind to G-
protein-coupled receptors can also trigger basophils and mast cells to release histamine via 
different signaling pathway (23, 26).  Additionally, complement components, such as the C3a 
and C5a “anaphylatoxins,” have also been shown to induce histamine release by mast cells (27).  
Many cytokines, including IL-3, IL-18, IL-33, GM-CSF and SCF, promote histamine synthesis 
(28-30).  In general, cytokines alone do not induce histamine release although it remains 
controversial whether IL-33 can have this effect. Some reports describe that IL-33 stimulates 
histamine release (31, 32), while other reports dispute this (33, 34).  It is suggested that IL-33 
alone does not induce histamine release by basophils, but enhances histamine release in response 
to IgE/FcεRI crosslinking (35) (Figure 2). 
 
Additional histamine-producing cells have also been identified, including T cells (36), dendritic 
cells (37), macrophages (38, 39) and epithelial cells (40, 41) (Figure 2).  In contrast to mast cells 
and basophils, these cells produce relative small quantities of histamine and do not store it in 
their cytoplasm (42).  The small amounts of histamine that they produced are released without 
external stimulation (42).  The biological significance of the small amounts of histamine 
produced by these minor histamine-producing cells remains unclear.  Cell type-specific deletion 
of the Hdc gene, which encodes histidine decarboxylase, an enzyme essential for histamine 
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synthesis, would shed light on the role of histamine synthesis and secretion by the minor 
histamine-producing cells.   
 
HISTIDINE DECARBOXYLASE AND HISTAMINE SYNTHESIS IN MAMMALS 
After several groups purified mammalian HDC protein from fetal rat liver and mouse 
mastocytoma P-815 cells (43-45), a  cDNA that encodes this protein was subsequently cloned 
(46, 47).  The Hdc gene encodes HDC protein, which has a molecular mass of 74 kDa and is a 
proenzyme with little or no enzyme activity. Once the proenzyme is cleaved at the site near its c-
terminus, presumably by Caspase-9, it yields a 53 kDa N-terminal and a 20 kDa C-terminal 
subunit.  The 20 kDa C-terminal subunit is believed to possess inhibitory activity (48).  The 53 
kDa N-terminal subunit forms a homodimer that is an active decarboxylase (48, 49).  HDC is the 
primary enzyme that catalyzes histamine synthesis. Mice deficient in the Hdc gene fail to 
synthesize histamine and have reduced or absent IgE-mediated anaphylactic responses (50-53). 
Several potent HDC inhibitors have been identified, including the histidine derivatives α-
fluoromethyl histidine, histidine methyl ester and pirodoxal histidine methyl ester (54-56).  
However, these HDC inhibitors have not been further developed for clinical use.  
 
HDC GENE EXPRESSION AND HISTAMINE SYNTHESIS IN BASOPHILS AND 
MAST CELLS 
 
Hdc gene expression and histamine synthesis are regulated both positively and negatively by a 
range of factors.  Notably, crosslinking of FcεRI by antigen binding to FcεRI-associated IgE 
increases mast cell Hdc mRNA expression and histamine synthesis (57, 58). These mast cell 
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activation-induced increases in Hdc mRNA expression and histamine synthesis are also induced 
by phorbol 12-myristate 13-acetate (59). Hdc mRNA expression and histamine synthesis also 
increase as immature mast cells undergo maturation. Bone marrow-derived mast cells (BMMCs) 
appear immature because they contain relatively little histamine and express relatively low levels 
of FcεRI (60). These immature mast cells develop into mature mast cells with higher amounts of 
histamine in vivo if they are adoptively transferred into the peritoneal cavity (61).  However, it is 
not clear if in vivo exposure to IgE promotes maturation and increases Hdc mRNA expression.  
 
In this regard, we demonstrated that chlorotoxin, which induces mast cell maturation (62), 
strongly upregulates Hdc gene expression in BMMCs within few hours after the treatment (5).  
The mechanism by which chlorotoxin enhances Hdc gene transcription remains to be 
determined.  It is conceivable that chlorotoxin activates mast cells by binding to an acidic 
glycosphingolipid, ganglioside G, that has been shown to be expressed on the mast cell surface 
(62).  Chlorotoxin-triggered signals in mast cells then activate transcription factors that directly 
and rapidly promote Hdc gene transcription. It is unknown whether bacteria in the gut of allergic 
patients can promote Hdc mRNA and histamine synthesis by producing substances similar to 
chlorotoxin.   
 
In line with the notion that factors promoting mast cell maturation also enhance histamine 
synthesis, cytokines that promote basophil and mast cell maturation, such as IL-3, IL-18, IL-33, 
GM-CSF and SCF, have also been reported to increase HDC activity (28-30, 63).  It is unclear 
whether these cytokines regulate Hdc gene transcription by increasing the expression of the 
genes that produce Hdc gene-activating transcription factors or by activating already produced 
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transcription factors to induce transcription of the Hdc gene.  Other substances, including 
chemokines, neuropeptide substance P, and IL-1α have also been reported to induce Hdc mRNA 
and histamine synthesis (64, 65).  
 
In contrast, mitochondrial uncoupling protein 2, a mitochondrial transporter protein that transfers 
anions from the inner to the outer mitochondrial membrane and protons from the outer to the 
inner mitochondrial membrane, inhibits Hdc mRNA expression and histamine synthesis, 
possibly by suppressing the production of reactive oxygen species (66).  Substances found in 
fruits and vegetables, such as quercetin (67), and in green tea, such as epigallocatechin gallate, 
also potently inhibit HDC (68). More detailed examination of negative regulators of Hdc mRNA 
expression should promote development of agents that may be able to prevent and treat food 
allergy and other histamine-mediated allergic inflammatory disorders. 
 
The human HDC gene is located in the 15q21.2 region of chromosome 15. It contains 12 exons 
(69) (Figure 3).  Eight predicted isoforms can be generated by alternative splicing and two actual 
isoforms have been described (70). HDC mRNA is expressed broadly in many organs, with the 
highest expression levels found in the gallbladder, stomach and lung (71). Because the RNA-seq 
data for normal tissues in the Human Protein Atlas were obtained from intact tissues, it is not 
clear whether the human HDC gene is expressed predominantly in known histamine-producing 
cells, such as mast cells and enterochromaffin-like cells (ECL) in high HDC-expressing tissues, 
or predominantly in other cell types in those tissues. In contrast to the human Hdc gene, the 
mouse HDC gene is located in chromosome 2 (72). It resembles the human gene in that it 
contains 12 exons, is expressed broadly in many tissues with the highest expression levels in 
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lung, ovary and subcutaneous fat pads (72, 73) and is 86% homologous with the human gene 
(https://www.ncbi.nlm.nih.gov/homologene/20490); however, there are only 3 predicted 
isoforms and no isoform, other than the classical one, have been found for murine Hdc (72).  
 
There is still limited knowledge of how Hdc gene expression is regulated transcriptionally. Most 
previous work has concentrated on the promoter region of this gene. Deletion analysis of Hdc 
promoter-driven luciferase reporter gene transcription demonstrated that the transcription factor 
SP1 binds to a GC box (GGGGCGGGG) found in both the human and mouse Hdc gene 
promoters (72, 74). Several promoter elements have been reported to negatively regulate Hdc 
gene transcription. For example, the transcription factors YY1 and KLF4 have been shown to 
negatively regulate the Hdc gene by suppressing SP1 in a gastric cancer cell line (75, 76).  
 
In contrast, Hdc gene expression is positively regulated by the transcription factor GATA 
binding protein 2 (GATA2), a member of the GATA family of transcription factors. GATA2 is 
critical for survival and proliferation of hematopoietic stem cells (77, 78), granulocyte-monocyte 
progenitor differentiation (79), and basophil and mast cell differentiation (80, 81) and is required 
for connective tissue mast cell development (5).  In contrast, basophil development is not 
affected in connective tissue-specific Gata2-deficient mice (5).  We have also found that 
mucosal and connective tissue-specific Gata2-deficient mice fail to develop both mucosal and 
connective tissue mast cells, indicating that GATA2 is required for both mucosal and connective 
tissue mast cell development (Li et al., unpublished data).  To distinguish the role of GATA2 in 
regulating the Hdc gene from its role in mast cell development, we used an inducible gene 
deletion method to delete the Gata2 gene from mast cells after they had fully differentiated.  In 
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this inducible gene deletion model, the enzyme Cre is fused to the estrogen receptor (ER) and the 
ER-Cre fusion product is induced to enter the cell nucleus to cleave a floxed gene of interest by 
the ER ligand 4-hydroxytamoxifen (82). Using this method, we demonstrated that GATA2 plays 
a critical role in regulating Hdc gene expression in even fully differentiated mast cells. However, 
in contrast to its role in mast cell development, GATA2 is not needed for survival of fully 
differentiated mast cells (83).  
 
More recently, our group has used active histone mark ChIP and reporter gene transcription 
assays to identify and characterize two Hdc enhancers in mast cells. Epigenomic studies 
demonstrate that monomethylation of lysine 4 on histone 3 (H3K4me1) marks genes that are 
poised to be transcribed, whereas acetylation of lysine 27 on histone 3 (H3K27ac) identifies 
genes that are actively being transcribed. The combined presence of H3K4me1 and H3K27ac 
modifications predicts enhancer activity (84-88). Our H3K4me1 and H3K27ac ChIP-seq analysis 
of BMMCs identified two putative Hdc enhancers located -8.8 kb upstream and +0.3 kb 
downstream from the transcription start site (TSS) of the Hdc gene (Figure 1). We demonstrated 
that the -8.8 kb Hdc enhancer, but not the +0.3 kb Hdc enhancer, increases minimal Hdc 
promoter activity in a luciferase reporter gene transcription assay. The transcription factor MITF 
binds to the -8.8 Hdc enhancer and drives its enhancer activity. Indeed, MITF overexpression 
largely restores Hdc gene expression in Gata2-deficient mast cells. Our study also suggests that 
GATA2 induces MITF and that these two transcription factors together direct full Hdc gene 
transcription in mast cells in a feed-forward manner. However, it is not certain that the -8.8 kb 
Hdc enhancer is fully responsible for positive regulation of the Hdc gene, because in vivo 
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importance of the +0.3 kb Hdc enhancer in Hdc gene transcription cannot be ruled out by the 
luciferase reporter gene transcription assay alone (5).  
 
Despite remarkable progress in genome-wide annotation of potential enhancers, functional 
validation of annotated enhancers remains an unmet challenge. Transgenic mice, reporter gene 
assay, and CRISPR/Cas9 genome editing have been used to validate the biological functions of 
enhancers identified by histone marks. Each of these methods has its strengths and weaknesses 
(89, 90). The reporter gene assay has been widely used to assess enhancer activity. It is simple, 
rapid and efficient at assessing promoter and enhancer activity in transiently or stably transfected 
cell lines. The limitation of the transient reporter gene assay is that it does not measure promoter 
and enhancer activity in the context of chromatin. Despite this disadvantage, this reductionist 
approach is useful for assessing binding of transcription factors to cis regulatory elements in 
accessible regions. It has been reported that ~60% of annotated enhancers show enhancer activity 
by the luciferase reporter gene assay (86, 91-94).  The in vivo function of the -8.8 Hdc enhancer 
requires further investigation.  
 
HISTAMINE SYNTHESIS IN THE CENTRAL NERVOUS SYSTEM AND THE 
STOMACH 
 
In addition to its activity as a vasoactive mediation, histamine is a neurotransmitter and a 
regulator of gastric acid secretion. HDC mRNA is expressed in the brain exclusively in the basal 
ganglia (95). Specific ablation of histaminergic neurons leads to repetitive movements (96), that 
resemble the signs of Tourette syndrome (97). Consistent with this, a nonsense mutation at the 
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human HDC gene (W317X) has been identified in a family of patients with this syndrome (97, 
98) and mice completely deficient in Hdc gene transcription develop a Tourette-like syndrome 
(97, 99). However, the mechanisms involved in Hdc gene regulation in the basal ganglia are 
currently unknown. In the stomach, histamine is synthesized in ECL and is released from these 
cells upon gastrin and acetylcholine stimulation. The released histamine then stimulates parietal 
cells to secrete stomach acid (25, 100). Mice deficient in the Hdc gene fail to fully acidify their 
gastric contents (100), which can lead to indigestion, diarrhea, constipation or rectal itching 
(101). Clinically, histamine 2 (H2) receptor antagonists, such as ranitidine, are currently used to 
ameliorate stomach hyperacidity and peptic ulcer disease by blocking this receptor on the 
hydrochloric acid-producing parietal cells in the stomach (Ranitidine: a review of its 
pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Brogden RN, 
Carmine AA, Heel RC, Speight TM, Avery GS. Drugs. 1982 Oct;24(4):267-303.). At present, it 
is not known how the Hdc gene is regulated in ECL cells. It is most likely that different 
transcription factors are used to regulate the Hdc gene in basal ganglia and ECL cells.  
 
CONCLUDING REMARKS 
 
HDC is the rate-limiting enzyme for histamine synthesis.  Understanding transcriptional 
regulation of the Hdc gene will advance our knowledge about how this gene detects extracellular 
stimuli and increases its transcription, leading to histamine synthesis, replenishment and 
accumulation that exacerbate allergic inflammation and anaphylaxis. Fine mapping of critical 
transcription factors and their authentic binding sites within the Hdc promoter and enhancers 
should promote identification of regulatory variants that influence allergy susceptibility and 
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severity. Today, Bill Paul’s teaching and his large body of work on IL-4 continues to inspire our 
fascination with type 2 immunity. 
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FIGURE 1 | Histamine synthesis 
 
FIGURE 2 | Histamine-producing cells and stimuli that trigger histamine release.  
 
FIGURE 3 | Genomic structures of the human and mouse HDC gene.  
Red bars indicate the enhancers we described.  
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